Animal studies looking at clinically relevant outcomes show longer median survival of rats with 9 L gliomas after three weekly treatments of FUS aided doxorubicin18, as well as longer survival of rats with HER-2 amplified brain tumors after FUS delivered NK-92 cells with HER2 specific receptors19. Here, ERBB2 is linked to central nervous system cancer.